SEDAR+ filings

Tryggvi has entered into a non-binding letter of intent in respect of a proposed qualifying transaction with Slocan Ridge Holdings Inc., previously the subject of a terminated transaction with Halcyon Capital.

Board of Directors approves final investment decision on the 640,000 bbl/d Cardinal midstream expansion; first incremental volumes expected in the second half of 2027.

Veldmar Therapeutics has closed its previously announced bought-deal offering for gross proceeds of $22.0M.

The Trust declared a Q2 cash distribution of $0.28 per unit, payable July 15, 2026.

The previously announced qualifying transaction with Slocan Ridge Holdings has been terminated. The Company will continue to evaluate alternative transactions.

The Company continues to evaluate qualifying transaction opportunities. No revenue. General and administrative expenses for the period were $182,000.

Research expenses of $3.6M reflect IND-enabling work on VLD-117. Cash runway is projected into Q1 2027 following the June financing.

Phase II drilling is on hold pending closing of the previously announced bridge financing. Working capital deficiency widened to $2.1M during the quarter.

Throughput on the Cardinal pipeline averaged 318 Mboe/d. Distributable cash flow per share rose 6% year over year.

Revenue of $4.1M was driven by a single Merevix milestone. Phase II topline data for CSB-204 is now expected in H2 2026.

Revenue: nil. Net loss: $(14,820). Cash: $18,402. Unqualified audit opinion from Ashford Whitman LLP.

Revenue: $1,884,200. Net income: $612,400. Unqualified audit opinion from Pellier Grandeau.

Revenue for the year was $14.2 million, a decrease of $3.8 million from the prior year, primarily due to the deferred recognition of milestone payments under the Merevix licensing arrangement.

Revenue: $14,213. Net loss: $(38,610). Cash and equivalents: $112,840. Reported in thousands of Canadian dollars.

Royalty revenue for the year was $214.6 million across 28 producing streams. The Trust declared distributions of $1.12 per unit, consistent with prior guidance.

Revenue: $214,610. Net income: $138,402. Unqualified audit opinion from Pellier Grandeau.

CSB-204 demonstrated a 41% objective response rate at the interim analysis. The Company expects regulatory approval and commercial launch on its previously disclosed timeline.

Halcyon has entered into a non-binding letter of intent in respect of a proposed qualifying transaction with Slocan Ridge Holdings Inc., a privately-held lithium exploration company.

The Company continues to evaluate qualifying transaction opportunities. A $1,200,000 unsecured loan was advanced to Northpeak Lithium Corp., a related party.

The Slocan Ridge Project remains the Company's principal asset. Management expects to commence Phase II drilling in Q4 2024, contingent on completion of the financing currently under negotiation.

Notice is given pursuant to NI 51-102 that Brookmere & Co. has resigned as auditor effective May 31, 2024. The board has appointed Crescent Audit Group to fill the vacancy until the next annual meeting.

Filed 28 days after the 90-day deadline under NI 51-102. Going concern note: the Company has incurred losses since inception and requires additional financing to continue operations.

The Company will be fully funded for the 2024 exploration program upon closing of the previously announced private placement, expected in early Q2 2024.

Revenue for the year was $18.0 million, including $4.0 million of milestone payments from Merevix recognized in full upon receipt during Q3 2023.

Northpeak Lithium Corp. is pleased to announce the appointment of Grayson Holt as Strategic Advisor to the board.

Articles of Amendment filed under the Business Corporations Act (British Columbia) changing the name of the Company from Boreal Cannabis Holdings Ltd. to Northpeak Lithium Corp.

Articles of Amendment changing the Company's name from Pacific Cobalt Ridge Resources Inc. to Boreal Cannabis Holdings Ltd.